Bausch + Lomb Launches Xipere for Macular Edema
Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
Bausch + Lomb has launched Xipere (triamcinolone acetonide injectable suspension), the first therapy approved the treatment of macular edema associated with uveitis, a form of eye inflammation.
Macular edema is the buildup of fluid in the macula, which causes retinal swelling and distorted vision, and if left untreated, may lead to permanent vision loss. It is delivered using the SCS Microinjector developed by Clearside Biomedical.
Steven Yeh, M.D.
“Suprachoroidal administration, which provides exceptional access and high bioavailability to the posterior segment of the eye, has been well tolerated by patients, Steven Yeh, M.D., professor of Ophthalmology and director of Retinal Disease and Uveitis, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, and principal investigator for the Xipere phase 3 pivotal study, said in a press release.
“This administration technique is unlike traditional intraocular administration, and therefore, training for how to properly inject patients with this new medicine is important. I encourage eye care professionals to take advantage of the trainings being offered by Bausch + Lomb," he said.
The FDA approved Xipere in October 2021.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
